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Background. Broadly neutralizing monoclonal antibodies (bnMAbs) may promote clearance of HIV-1-expressing cells through 
antibody-dependent cell-mediated cytotoxicity. We evaluated the effect of the CD4-binding site bnMAb, VRC01, on measures of 
HIV-1 persistence in chronically infected individuals.
Methods. A5342 was a phase 1, randomized, double-blind, placebo-controlled, parallel-arm study. Participants on effective 
antiretroviral therapy (ART) were randomized to receive 2 infusions of VRC01 (40 mg/kg) at entry and week 3, and 2 infusions of 
placebo (saline) at weeks 6 and 9; or 2 infusions of placebo at entry and week 3, and 2 infusions of VRC01 at weeks 6 and 9.
Results. Infusion of VRC01 was safe and well tolerated. The median fold-change in the cell-associated HIV-1 RNA/DNA ratio 
from baseline to week 6 was 1.12 and 0.83 for the VRC01 and placebo arms, respectively, with no significant difference between 
arms (P = .16). There were no significant differences in the proportions with residual plasma viremia ≥1 copies/mL or in phorbol 
12-myristate 13-acetate/ionomycin-induced virus production from CD4+ T cells between arms (both P > .05).
Conclusions. In individuals with chronic HIV-1 infection on ART, VRC01 infusions were safe and well tolerated but did not
affect plasma viremia, cellular HIV-1 RNA/DNA levels, or stimulated virus production from CD4+ T cells.
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Effective antiretroviral therapy (ART) inhibits HIV-1 repli-
cation and reduces HIV-1 plasma RNA to levels below the 
detection of clinical assays; however, following interruption of 
ART, HIV-1 RNA generally rebounds to pre-ART levels within 
weeks. HIV-1 is able to persist despite ART because of the estab-
lishment of latent infection in long-lived cells, including resting 
memory CD4+ T cells [1, 2]. The latent cellular reservoir decays 
very slowly over time (T1/2 of 44 months) on ART alone [3]; thus 
alternative therapies are being explored to accelerate its decay. 
Monoclonal antibodies have been developed as treatment for a 
variety of conditions including cancer, autoimmune disorders, 
and infections. Such antibodies directed at the HIV-1 envelope 
can promote antibody-dependent cell-mediated cytotoxicity 
(ADCC) and may be capable of killing HIV-1-expressing cells 
[4]. Several potent, broadly neutralizing monoclonal antibodies 
(bnMAbs) that bind to the HIV-1 envelope protein (env) have 
been isolated from HIV-1-infected individuals and are being 
developed for preventative and therapeutic use [5–7].
Studies in nonhuman primates provide evidence of the ther-
apeutic potential of bnMAbs in HIV-1 infection. Barouch et al. 
[8] administered the V3 glycan loop bnMAb PGT121 alone
and in combination with other bnMAbs to chronically infected, 
viremic (SHIV-SF162P3) rhesus macaques in a series of exper-
iments. Rapid declines in plasma viremia were observed within
7 days of the initial infusion and were sustained until the anti-
body levels became undetectable. Reductions in cell-associated
HIV-1 DNA in the peripheral blood, gastrointestinal mucosa,
and lymph nodes have been observed in treated animals [8].
Shingai et al. reported similar results in macaques chronically
infected with SHIV-AD8 using 2 bnMAbs, 1 against the CD4+
binding site (3BNC117) and the other against the V3 glycan
loop (10–1074) of the HIV-1 envelope [9]. These observations
indicate that bnMAbs can block cell-to-cell spread of simian
immunodeficiency virus (SIV) in the absence of ART. In add-
ition, analyses of viral decay kinetics suggest the clearance of
virus-infected cells, possibly through ADCC [10].
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Initial clinical studies in humans have been conducted for 
several HIV-1 bnMAbs to evaluate safety, pharmacokinetics, 
and antiviral activity for antibodies targeting the CD4 binding 
site (3BNC117 and VRC01) and the V3-glycan (10–1074) on 
the HIV-1 envelope [11–16]. These trials have demonstrated 
that the bnMAbs are safe at doses of up to 30 to 40 milligrams 
per kilogram, depending on the antibody. In the absence of pre-
existing bnMAb resistance, the bnMAbs demonstrated in vivo 
antiviral activity, leading to a decrease in plasma HIV-1 RNA on 
the order of 1 log10 copies/mL in the absence of ART; however, 
evidence of bnMAb resistance was detected in some individuals 
at baseline, and in the majority of subjects, a return to viremia 
occurred as antibody levels waned [12, 14–16]. Additionally, 
given alone, VRC01 or 3BNC117 was not sufficient to main-
tain viral suppression after withdrawal of ART in individuals 
who initiated ART in chronic or acute infection, although some 
delays in rebound were observed [11, 17, 18].
To date, there are limited data describing the in vivo effect of 
bnMAbs on the latent viral reservoir in individuals with sup-
pressed viremia on ART [14]. Given the evidence that bnMAbs 
can block cell-to-cell HIV-1 spread and potentially mediate the 
killing of infected cells expressing the HIV-1 envelope, there is 
great interest in the role of single or multiple bnMAbs, alone 
or in combination with latency-reversing agents, on latent HIV. 
We conducted a randomized controlled clinical trial to evaluate 
whether VRC01, a CD4-binding site bnMAb, affects the per-
sistence of HIV-1. We measured several indicators of HIV-1 
persistence, before and after VRC01 infusions, including the 
proportion of CD4+ T cells expressing HIV-1 RNA and the 
proportion of individuals with residual plasma viremia among 
chronically infected individuals on effective ART.
METHODS
Study Design and Participants
A5342 was a phase I, double-blind, randomized, placebo-con-
trolled, parallel-arm study conducted at AIDS Clinical Trials 
Group (ACTG) sites in the United States (ClinicalTrials.gov 
Identifier: NCT02411539). Eligible participants were HIV-1-
infected adults, between 18 and 65  years of age, body weight 
between 53 and 115 kilograms (inclusive), on continuous ART 
for at least 2 years and with a CD4+ T-cell count ≥200 per mm3, 
plasma HIV-1 RNA less than the limit of detection of standard 
clinical assays for at least 24 months and less than 40 copies/mL 
at screening, and acceptable laboratory parameters. Pregnant or 
breastfeeding women and individuals with chronic hepatitis B or 
hepatitis C infection, prior receipt of any humanized or human 
monoclonal antibody, or recent or current use of immunomod-
ulators were excluded. Written informed consent was obtained 
from each study participant. The study protocol was reviewed 
and approved by an institutional review board at each study site.
Participants were randomized equally to 2 arms at study 
entry (week 0). Each participant received 2 infusions of VRC01 
and 2 placebo infusions (normal saline). Arm A  participants 
received VRC01 40 mg/kg by intravenous infusion over 30 to 
60 minutes at week 0 and week 3, and saline placebo infusion 
at weeks 6 and 9. Arm B participants received placebo infusions 
at week 0 and week 3 and VRC01 infusions at weeks 6 and 9 
(Figure 1). Placebo infusions were 0.9% sodium chloride and 
were the same volume as the VRC01 infusions. The intravenous 
bags were covered with an amber bag and labeled identically to 
maintain blinding of the participants and clinical staff.
After screening, study visits were completed at pre-entry, 
entry (week 0), weekly for weeks 1–12, and at weeks 15, 18, 
and 30. Plasma HIV-1 RNA was measured at a central labora-
tory at entry and weeks 3, 6, 9, 12, 18, and 30 using the Abbott 
M2000 assay. CD4+ T-cell counts were obtained at entry and 
weeks 6, 12, 18, and 30. Adverse events were assessed by site 
investigators and were graded using the National Institutes of 
Health Division of AIDS Table for Grading the Severity of Adult 
and Pediatric Adverse Events (version 2.0). In addition, adverse 
event attribution to study treatment was reviewed by the core 
team blinded to study treatment.
Specialized Laboratory Measurements
Plasma HIV-1 RNA Single-Copy Assay
The single-copy HIV-1 RNA assay (SCA) targeting integrase 
was performed according to published methods [19] on plasma 
samples obtained at screening and weeks 0, 1 (Arm A), 3, 4 (Arm 
A), 6, 7 (Arm B), 9, 10 (Arm B), 12. In brief, 3 to 4.5 mL of dou-
ble-spun plasma was digested with proteinase K in guanidium 
hydrochloride and precipitated with glycogen and isopropanol, 
followed by a 70% ethanol wash. RNA was reverse-transcribed 
to cDNA, and quantitative polymerase chain reaction (qPCR) 
was performed targeting the integrase region of pol. The limit of 
detection of the SCA ranged from 0.4 to 1 copies/mL, depend-
ing on the volume of plasma available.
Total CD4+ T-Cell-Associated HIV-1 RNA and DNA
Cellular HIV-1 RNA and DNA were measured in total CD4+ 
T cells by ultrasensitive qPCR, as previously described [20]. In 
brief, total CD4+ T cells were isolated from peripheral blood 
mononuclear cells (PBMCs) by negative selection (Stem Cell 
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Figure 1. Study design.
Effect of VRC01 on HIV-1 Persistence • OFID • 3
extracted as described [20]. Half of the extract was used for 
HIV-1 DNA and CCR5 qPCR, and the other half was treated 
with DNAse-I (Promega), reverse-transcribed, and assayed for 
unspliced HIV-1 RNA by qPCR targeting integrase using the 
same primers and probes as for SCA.
Total Virus Recovery Assay 
Total CD4+ T cells were isolated from PBMCs (Stem Cell) and 
cultured (3–6 replicates of 1 million cells/well) in phenol red–
free R10 media with or without phorbol 12-myristate 13-acetate 
(PMA)/ionomycin (Iono) for 7 days in the presence of 300 mM 
of efavirenz and raltegravir as previously described [21]. Total 
induced HIV-1 RNA was quantified in culture supernatants 
(pooled from replicate wells and tested in duplicate) by qPCR at 
pre-entry, week 6, and week 12.
VRC01 Levels
VRC01 levels in serum were measured as previously described 
at every visit from entry to week 30; on infusion days, samples 
were collected both pre-infusion and 30 to 60 minutes postin-
fusion [13]. Anti-VRC01 antibody was measured in serum at 
week 18 or week 30 as previously described [13].
Study Product
VRC01 was manufactured by the VRC Vaccine Pilot Plant, oper-
ated by Leidos Biomedical Research, Inc. (Frederick, MD) under 
good manufacturing practice, and purified product was vialed at 
a concentration of 100 ± 10 mg/mL as previously described [13].
Statistical Analysis
The co-primary objectives of the study were to assess the safety 
and tolerability and to determine the efficacy of 2 intravenous 
infusions of VRC01 administered 3 weeks apart in HIV-1-
infected participants on effective ART. The primary efficacy 
outcome measure was the change in cell-associated HIV-1 
RNA/DNA ratio in total CD4+ cells from baseline to week 6 
and was compared between the 2 randomized arms using the 
Wilcoxon rank-sum test at a 10% significance level. The sec-
ondary outcome measure was change in cell-associated HIV-1 
RNA/DNA ratio from pre-VRC01 dosing to post-VRC01 dos-
ing combining participants from both arms (Arm A: from base-
line to week 6; Arm B: from week 6 to week 12) and was assessed 
using the Wilcoxon signed rank test at a 5% significance level. 
Differences in medians between the 2 randomized arms and 
from pre-VRC01 to post-VRC01 were estimated by 95% con-
fidence interval using Hodges-Lehmann estimate under the 
assumption that the 2 distributions are alike in shape and 1 dis-
tribution is shifted upward or downward by an amount rela-
tive to the other distribution. The maximal lower limit across 
all HIV-1 RNA SCA results was 1 copy/mL. HIV-1 RNA SCA 
values below the maximal detection limit were imputed with a 
value of half the limit (0.5 copies/mL). The proportion of par-
ticipants with SCA ≥1 copies/mL was compared between the 
randomized arms using the Fisher's exact test, and differences 
in the proportions pre- to post-VRC01 infusions were assessed 
using McNemar’s test. Virologic outcomes were analyzed after 
log10 transformation. Both safety and efficacy analyses used an 
as-treated approach restricted to randomized participants who 
received at least 1 dose of study treatment. All reported P values 
were nominal and not adjusted for multiple comparisons.
RESULTS
Accrual and Participant Characteristics
A total of 40 participants were enrolled and randomized 
between August 2015 and March 2016. The baseline charac-
teristics of the enrolled participants are shown in Table 1, and 
the disposition of all study participants is displayed in Figure 2. 
At study entry, the median age was 52 years, and the median 
CD4+ T-cell count was 696 per mm3 (Table 1). Baseline char-
acteristics were generally balanced between treatment arms; 
however, Arm B participants were older and had lower baseline 
CD8 counts than those in Arm A. Three participants prema-
turely discontinued the study: 2 participants (1 from each arm) 
discontinued before week 12 and did not have samples drawn 
for the primary efficacy assessment at week 6; and 1 Arm A par-
ticipant discontinued after week 18. All participants received at 
least 1 infusion, and 37/40 (93%) completed all VRC01/placebo 
infusions per protocol.
VRC01 given as 2 intravenous doses of 40 mg/kg was safe and 
well tolerated. No grade 3 or higher treatment-related adverse 
events were reported during study follow-up. Two participants, 1 
from each arm, did not complete scheduled infusions due to being 
off study prematurely. In total, 5 participants had mild to moder-
ate (grade 1 and 2) clinical symptoms that were deemed possibly, 
probably, or definitely related to the infusions. Infusion-related 
adverse events were uncommon and consistent with expected 
monoclonal antibody infusion reactions. One VRC01 infusion 
was discontinued after 94% of the volume was administered due 
a grade 2 rash and grade 1 pruritis, which resolved within hours; 
this participant again developed grade 2 rash and grade 1 pruritis 
with the second infusion, but the full dose was administered as 
elected by the participant and the site investigator. A second par-
ticipant developed a grade 1 rash with the first VRC01 infusion 
that was determined to be possibly related; the rash did not recur 
with the second infusion. Three participants experienced flu-like 
symptoms; for 1 participant, the symptoms occurred on the day of 
VRC01 infusion for both doses, and for the other 2 participants, 
the symptoms were temporally associated with placebo. No par-
ticipants experienced virologic failure during the study, defined 
as confirmed plasma HIV-1 RNA >200 copies/mL. CD4+ T-cell 
counts were stable throughout the study period.
VRC01 Pharmacokinetics
The serum trough concentrations of VRC01 measured 3 weeks 
after the first infusion ranged from 41.6 to 239.4 µg/mL (median, 
112.2  µg/mL); all except 1 participant had concentrations 
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Assessed for eligibility (n = 56)
Ransomized (n = 40)
Allocated to Arm A (n = 20)
Completed 4 scheduled infusions (n = 19)
Did not complete scheduled infusions (n = 1)
Allocated to Arm B (n = 20)
Completed 4 scheduled infusions (n = 19)
Did not complete scheduled infusions (n = 1)
Completed protocol follow-up (n = 18)
Prematurely discontinued (n = 2)
Moved away from study site (n = 2)
Completed protocol follow-up (n = 19)
Prematurely discontinued (n = 1)
Investigator/clinician discretion (n = 1)
Safety and pharmacokinetics (n = 20)
Analyzed (n = 20)
Virologic outcomes (n = 19)
Safety and pharmacokinetics (n = 20)
Analyzed (n = 20)
Virologic outcomes (n = 19)
Excluded (n = 16)
Not meeting inclusion criteria (n = 9)
Declined to participate (n = 2)
Other reasons (n = 5)
Figure 2. Consolidated Standards of Reporting Trials (CONSORT) diagram.







Age, median (IQR), y 45 (32–54) 56 (50–59) 52 (41–58)
Male sex, No. (%) 17 (85) 20 (100) 37 (93)
Race/ethnicity, No. (%)
 White, non-Hispanic 13 (65) 14 (70) 27 (68)
 Black, non-Hispanic 3 (15) 4 (20) 7 (18)
 Hispanic 4 (20) 2 (10) 6 (15)
Duration of ART, median (IQR), y 7.3 (4.5–10.6) 6.9 (5.4–10.7) 6.9 (5.2–10.7)
ART regimen at entry, No. (%)
 NNRTI + NRTIs 6 (30) 5 (25) 11 (28)
 PI + NRTIs 4 (20) 6 (30) 10 (25)
 InSTI + NRTIs 7 (35) 6 (30) 13 (33)
 Other 3 (15) 3 (15) 6 (15)
CD4 cell count, median (IQR), cells/mm3 701 (594–952) 685 (535–843) 696 (559–889)
CD8 cell count, median (IQR), cells/mm3 801 (490–1210) 617 (480–744) 663 (490–936)
CD4/CD8 ratio, median (IQR) 0.9 (0.7–1.2) 1.1 (0.9–1.8) 1.0 (0.8–1.4)
Cell-associated HIV-1 RNA,a median (IQR), log10 copies/10
6 CD4 1.60 (0.90–2.09) 1.38 (0.90–2.03) 1.53 (0.90–2,04)
Cell-associated HIV-1 DNA,b median (IQR), log10 copies/10
6 CD4 3.05 (2.42–3.20) 3.00 (2.53–3.18) 3.03 (2.42–3.18)
Cell-associated HIV-1 RNA/DNA ratio,a median (IQR) 0.05 (0.02–0.10) 0.03 (0.02–0.05) 0.04 (0.02–0.07)
Abbreviations: ART, antiretroviral therapy; InSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse 
transcriptase inhibitor; PI, protease inhibitor. 
an = 19 for Arm A and n = 19 for Arm B.
bn = 20 for Arm A and n = 19 for Arm B.
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>50 µg/mL. The trough concentrations 3 weeks after the second 
dose were higher, with a range of 51.7 to 340.9 µg/mL (median,
133.5  µg/mL). All participants had detectable serum levels of
VRC01 at the time point 6 weeks after the final dose, with a
median level (range) of 42.1 (9.9–265.2) ug/mL. Anti-VRC01
antibody was not detected in any study participants (n = 38).
Virologic Outcomes
The median baseline (week 0) values for cell-associated HIV-1 
RNA (CAR) and HIV-1 DNA (CAD) were 1.53 and 3.03 log10 
copies/million CD4+ T cells, respectively. The median ratio of 
CAR/CAD was 0.04 and was similar between arms (Table 1). 
The primary and secondary virologic outcome measures are 
summarized in Table 2. No significant difference was observed 
in the primary efficacy outcome of change in HIV-1 CAR/CAD 
ratio from baseline to week 6 between VRC01 and placebo 
(median fold-change, 1.12 vs 0.83; 95% confidence interval [CI] 
on the difference in median fold-change between the 2 arms, 
0.75–2.42; P = .16). Similarly, there was no difference from pre- 
to post-VRC01 time points with both arms combined (median 
fold-change, 1.24; 95% CI, 0.83–1.69; P = .29).
HIV-1 plasma RNA ≥1 copies/mL was present at baseline in 
22/40 (55%) participants. At week 6, there was no difference in 
the proportion with SCA ≥1 copies/mL between the arms (42% 
vs 37%; P = 1.0). Similarly, the proportion ≥1 copies/mL was 
not statistically different for the pre- to post-VRC01 time points 
for both arms combined (P = .59). No evidence of a change in 
the proportion of participants with SCA ≥1 copies/mL was seen 
at 1 and 3 weeks after each VRC01 infusion (data not shown).
The effect of VRC01 on HIV-1 persistence was also measured 
with an assay of PMA-ionomycin-induced HIV-1 RNA release 
into culture supernatants over 7 days from total CD4+ T cells 
[21]. The change in stimulated virus production (HIV-1 RNA 
copies/mL in supernatants) from baseline to week 6 was not sta-
tistically different between arms (–0.13 vs 0.12 log10 RNA cop-
ies/mL; P = .91), or from pre- to post-VRC01 time points with 
both arms combined (P = .85).
DISCUSSION
Many bnMAbs for HIV have been identified, and several are 
in clinical development for both the prevention and treatment 
of HIV-1 [5–7, 11–14, 16, 17, 22, 23]. These bnMAbs have 
anti-HIV-1 neutralization activity, but their impact on the per-
sistence of HIV-infected cells and on residual viremia in ART-
suppressed participants remains uncertain. In our study among 
individuals with chronic ART-suppressed HIV-1 infection, 2 
doses of VRC01 was safe and well tolerated but did not have a 
measurable impact on cellular HIV-1 RNA or DNA levels, cel-
lular HIV-1 RNA/DNA ratio, HIV-1 plasma viremia, or stimu-
lated virus production from total CD4+ T cells.
Notably, even among the subset of participants (n  =  22) 
with measurable plasma HIV-1 RNA by single-copy assay, we 
found no effect of VRC01 on residual viremia. Similarly, Lynch 
et  al. also observed no effect of VRC01 infusion on residual 
plasma virus in 2 participants with measurable HIV-1 RNA 
by SCA [14]. By contrast, in HIV-1-infected individuals who 
were not on ART with high plasma HIV-1 RNA, both VRC01 
and 3BNC117 administered as monotherapy were found to 
reduce plasma HIV-1 RNA by approximately 1 log10 copies/
mL in the absence of preexisting resistant variants [12, 14–16]. 
In untreated individuals, VRC01 likely lowers the abundant 
plasma viremia by blocking cell-to-cell spread of HIV-1 infec-
tion through its neutralization activity, rather than ADCC 
activity. By contrast, HIV-1 plasma RNA in individuals on 
long-term suppressive ART is more likely from the release of 
Table 2. Virologic Outcomes
Arm A Arm B
P Valueb
Arms A and B Combined
Change From Pre- to 
Post-VRC01 P Valuec
Change From Baseline to Week 6 
Median (Q1, Q3) Pre-VRC01 Values Post-VRC01 Values







































Stimulated virus production 













Week 6 P Valued P Valuee
Plasma HIV RNA ≥1 copies/mL 
by single-copy assay (%)
8/19 (42) 7/19 (37) 1.0 16/38 (42) 14/38 (37) – .59
aChanges in RNA/DNA ratios are shown as fold-change, calculated by dividing the RNA/DNA ratio at the later time point by the earlier time point.
bWilcoxon rank-sum test. 
cWilcoxon signed rank test. 
dFisher exact test. 
eMcNemar’s test.
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virus from stable reservoirs of infected cells rather than virus 
produced by ongoing, complete cycles of viral replication [24, 
25]. The lack of effect of virus neutralization activity of VRC01 
on residual viremia is consistent with numerous studies that 
have demonstrated the lack of effect of antiretroviral intensi-
fication on residual plasma viremia in the setting of effective 
ART [26–31]. In this study of individuals on effective ART, we 
hypothesized that VRC01 might still have an effect on persistent 
virus-expressing cells even in the absence of ongoing viral repli-
cation; unfortunately, we did not detect such an effect.
There are several potential explanations for the lack of 
response of residual HIV-1 in plasma to treatment with VRC01. 
First, it is possible that the residual viremia was from variants 
with preexisting resistance to VRC01. Prior studies have demon-
strated that 90% of circulating M-type isolates were susceptible 
to VRC01 with a 50% inhibitory concentration of 50 µg/mL or 
less [32, 33]. We were not able to perform susceptibility test-
ing of plasma virus in our study due to the very low levels of 
viremia, but it would be unlikely that all the participants with 
residual viremia would harbor HIV-1 variants in plasma that 
were resistant to VRC01. However, the viral variants that persist 
or emerge on ART may differ considerably from the variants 
present during untreated infection with high levels of virus pro-
duction and rapid cell turnover. Viral variants that persist on 
ART may be inherently resistant to antibody-mediated clear-
ance, or they may already be bound by autologous antibody 
that blocks binding of VRC01. Second, the residual virus in the 
plasma on ART may have other changes that render bnMAbs 
ineffective, including defective virus particles lacking envelope. 
In this regard, the quantity of the virus in the plasma is too low 
to determine whether it contains the envelope protein.
The administration of VRC01 also did not clearly impact the 
number or transcriptional activity of HIV-1-infected cells in 
blood, as measured by cell-associated HIV-1 RNA, DNA, or the 
ratio of RNA/DNA. It has been postulated that bnMAbs would 
enhance the clearance of HIV-infected cells expressing the enve-
lope protein through ADCC [10]. Lu et al. examined the effect 
of the combination of the bnMAbs 3BNC117 and 10–1074 on 
the percentage of HIV-infected cells that persist after adoptive 
transfer in mice [34]. These experiments using human CD4+ T 
cells infected with primary HIV-1 isolates from 4 individuals 
demonstrated greater clearance of infected cells in the bnMAb-
treated mice compared with an isotype control [34]. There are 
several possible reasons why a reduction in cell-associated HIV 
DNA or RNA was not observed in the current human clinical 
trial. Additionally, Cohen et al. have similarly reported a lack 
of effect of 3BNC117 infusions on the viral reservoir in 9 indi-
viduals, as measured by viral outgrowth from CD4 T cells [35]. 
The capacity for antibody binding to infected CD4 T cells varies 
among the bnMAbs. In vitro experiments performed by Mujib 
et al. and others have shown low levels of infected cell binding 
and ADCC for CD4 binding site antibodies, including VRC01 
and 3BNC117 [10, 36]. The clearance of infected cells by anti-
body requires the expression of envelope on the cell surface; 
however, only a small fraction of HIV-infected cells in blood 
express unspliced HIV-1 RNA [37]. It is not known what frac-
tion of cells express HIV-1 envelope protein, but it is expected to 
be low as not all transcripts are translated, some transcripts are 
from defective proviruses, and even for intact, fully expressed 
proviruses, HIV-1 envelope expression on the cell surface is 
likely transient and mostly occurs before budding [38]. In add-
ition, even if expressed on the cell surface, the envelope target 
density may be too low for VRC01 to have a measurable effect 
on the number of infected cells [38]. Finally, it is possible that 
VRC01 did not penetrate to the sites of potential virus produc-
tion, such as lymph node germinal centers.
Although high-dose VRC01 did not have a discernable effect 
on multiple measures of HIV-1 persistence, it was safe and well 
tolerated. Moreover, the activity of more potent and broader 
bnMAbs with longer half-lives and enhanced Fc-mediated 
effector functions should continue to be studied, alone and in 
orthogonal combinations of bnMAbs to enhance HIV-1 vari-
ant coverage. Clinical trials of combinations of bnMAbs and of 
bispecific antibodies will help define the role of antibody thera-
peutics in reducing or controlling HIV-1 reservoirs [39].
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